Literature DB >> 9987078

Effect of recombinant human erythropoietin on endothelial cell apoptosis.

R G Carlini1, E J Alonzo, J Dominguez, I Blanca, J R Weisinger, M Rothstein, E Bellorin-Font.   

Abstract

BACKGROUND: Recombinant human erythropoietin (rHuEPO) induces endothelial cell growth and angiogenesis in vitro. The mechanisms are unknown. Because an increase in endothelial cell survival could play a role in this process, we examined the effect of rHuEPO on lipopolysaccharide (LPS)-induced apoptosis in bovine pulmonary artery endothelial cells (BPAECs).
METHODS: Four groups of cells were studied. The first group was preincubated in serum-free medium followed by treatment with LPS. The second group was preincubated with rHuEPO followed by LPS. The third group was treated with only rHuEPO. Control cells were cultured in the absence of rHuEPO and LPS. Apoptosis was determined by flow cytometric DNA analysis, propidium iodide staining, cellular DNA fragmentation by ELISA, and gel electrophoresis.
RESULTS: LPS-treated cells showed an increase in hypodiploid DNA (36.4 +/- 6.1%) compared with controls (9.8 +/- 3.3%, P < 0.001). Preincubation with rHuEPO decreased this effect to 14.7 +/- 5.1% (P < 0.001). Apoptosis determined by propidium iodide was observed in 33 +/- 8% of LPS-treated cells, but in only 9 +/- 3% of cells preincubated with rHuEPO cells (P < 0.001). Similarly, DNA fragmentation was decreased in rHuEPO pretreated cells compared with LPS alone (0.155 OD +/- 0.02 vs. 0.538 +/- 0.09 OD, P < 0.001). DNA breakdown was observed in only LPS-treated cells.
CONCLUSIONS: These results suggest that rHuEPO prevents LPS-induced apoptosis in endothelial cells. This protective effect could be an important factor in the action of rHuEPO on vascular endothelium.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9987078     DOI: 10.1046/j.1523-1755.1999.00266.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  18 in total

1.  Induction of erythropoiesis using human vascular networks genetically engineered for controlled erythropoietin release.

Authors:  Ruei-Zeng Lin; Alexandra Dreyzin; Kristie Aamodt; Dan Li; Shou-Ching S Jaminet; Andrew C Dudley; Juan M Melero-Martin
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

2.  Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.

Authors:  Ahmed Mohyeldin; Huasheng Lu; Clifton Dalgard; Stephen Y Lai; Noam Cohen; Geza Acs; Ajay Verma
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

3.  Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology.

Authors:  Mohammed H El-Komy; John A Widness; Peter Veng-Pedersen
Journal:  Drug Metab Dispos       Date:  2011-01-05       Impact factor: 3.922

4.  Anemia as a risk factor for all-cause mortality: obscure synergic effect of chronic kidney disease.

Authors:  Yuji Sato; Shouichi Fujimoto; Tsuneo Konta; Kunitoshi Iseki; Toshiki Moriyama; Kunihiro Yamagata; Kazuhiko Tsuruya; Ichiei Narita; Masahide Kondo; Masato Kasahara; Yugo Shibagaki; Koichi Asahi; Tsuyoshi Watanabe
Journal:  Clin Exp Nephrol       Date:  2017-08-16       Impact factor: 2.801

5.  Receptor-based dosing optimization of erythropoietin in juvenile sheep after phlebotomy.

Authors:  Matthew Rosebraugh; John A Widness; Peter Veng-Pedersen
Journal:  Drug Metab Dispos       Date:  2011-04-01       Impact factor: 3.922

6.  Pleiotrophic actions of erythropoietin.

Authors:  Laurie Feldman; Arthur J Sytkowski
Journal:  Environ Health Prev Med       Date:  2003-01       Impact factor: 3.674

7.  Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.

Authors:  Thomas R Coleman; Christof Westenfelder; Florian E Tögel; Ying Yang; Zhuma Hu; Leanne Swenson; Henri G D Leuvenink; Rutger J Ploeg; Livius V d'Uscio; Zvonimir S Katusic; Pietro Ghezzi; Adriana Zanetti; Kenneth Kaushansky; Norma E Fox; Anthony Cerami; Michael Brines
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

Review 8.  Emerging therapies for chronic kidney disease: what is their role?

Authors:  Eswari Vilayur; David C H Harris
Journal:  Nat Rev Nephrol       Date:  2009-05-19       Impact factor: 28.314

9.  Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.

Authors:  Geza Acs; Paul J Zhang; Cindy M McGrath; Peter Acs; John McBroom; Ahmed Mohyeldin; Suzhen Liu; Huasheng Lu; Ajay Verma
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

10.  Attenuation of inflammation and apoptosis by pre- and posttreatment of darbepoetin-alpha in acute liver failure of mice.

Authors:  Khoi Le Minh; Katja Klemm; Kerstin Abshagen; Christian Eipel; Michael D Menger; Brigitte Vollmar
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.